Why Moderna Stock Gained 15.5% in March While the Market Plunged
Shares of clinical-stage biotech Moderna (NASDAQ: MRNA) rose 15.5% in March, according to data from S&P Global Market Intelligence.
That's a much better performance than it might seem at first glance, when you consider that last month the S&P 500 index returned negative 12.4%. The market sell-off is being driven by investors' fears about the economic impact of the novel coronavirus pandemic.
(In April, Moderna stock has continued to run. In the first two trading days of the month through Thursday, it's up 10.9%, whereas the broader market is down 3.8%.)
Source Fool.com
